Prashant Kesharwani
Overview
Explore the profile of Prashant Kesharwani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
362
Citations
4203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moosavian S, Amin M, Alavizadeh S, Jaafari M, Kesharwani P, Sahebkar A
Tissue Cell
. 2025 Mar;
95:102830.
PMID: 40068280
A promising strategy for improving the effectiveness, specificity and safety of cancer treatment is targeted medication delivery. Prostate-specific membrane antigen (PSMA) is an effective biomarker for tracking and treating prostate...
2.
Amini S, Navab F, Rouhani M, Jamialahmadi T, Bagherniya M, Kesharwani P, et al.
Eur J Pharmacol
. 2025 Mar;
997:177491.
PMID: 40057158
Oxidation of low-density lipoprotein (LDL) accelerates atherosclerosis. Vitamin E is a powerful fat-soluble antioxidant; some studies have shown its beneficial effects in reducing oxidized LDL levels. Due to the inconsistent...
3.
Askarizadeh F, Butler A, Kesharwani P, Sahebkar A
Food Chem Toxicol
. 2025 Mar;
200:115369.
PMID: 40043936
Natural compounds have garnered significant attention as potential therapeutic agents due to their inherent properties. Their notable qualities, including safety, efficacy, favorable pharmacokinetic properties, and heightened effectiveness against certain diseases,...
4.
Rehman U, Gupta G, Sahebkar A, Kesharwani P
Immunology
. 2025 Mar;
PMID: 40035403
Cancer immunotherapy has revolutionized treatment paradigms, but its efficacy is often curtailed by T-cell exhaustion and the suppressive tumour microenvironment. Recent studies reveal a novel mechanism of T-cell demise termed...
5.
Abianeh H, Kesharwani P, Sahebkar A
Int J Biol Macromol
. 2025 Feb;
306(Pt 1):141202.
PMID: 39971069
Tumor necrosis factor-alpha (TNF-α) is a pivotal cytokine in the pathogenesis of numerous inflammatory and autoimmune diseases. Precise and sensitive detection of TNF-α is essential for both clinical applications and...
6.
Aqil A, Yasmeen I, Parveen I, Nadaf A, Jiba U, Adil M, et al.
Eur J Pharmacol
. 2025 Feb;
:177354.
PMID: 39938857
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause.
The full Elsevier Policy on Article Withdrawal can...
7.
Nasiri R, Arefnezhad R, Baniasad K, Hosseini S, Jeshari A, Miri M, et al.
Tissue Cell
. 2025 Feb;
93:102772.
PMID: 39923649
Myocardial ischemia-reperfusion injury (MIRI) is a significant challenge in the treatment of ischemic heart disease (IHD), arising as a complication from reperfusion therapies designed to restore blood flow after an...
8.
Chauhan M, Chandra J, Gupta G, Ramaiah R, Hani U, Kesharwani P
Int J Pharm
. 2025 Jan;
671:125273.
PMID: 39870257
The rising incidence of skin disorders has necessitated the exploration of innovative therapeutic modalities that harness the beneficial properties of natural compounds. Phytoconstituents, renowned for their diverse pharmacological attributes, present...
9.
Shahbaz S, Mokhlesi A, Sadegh R, Rahimi K, Jamialahmadi T, Butler A, et al.
Tissue Cell
. 2025 Jan;
93:102723.
PMID: 39823704
Mobility disability is a common condition affecting older adults, making walking and the performance of activities of daily living difficult. Frailty, cachexia and sarcopenia are related conditions that occur with...
10.
Ali M, Almoyad M, Wahab S, Sahebkar A, Gorain B, Kaur H, et al.
Int J Pharm
. 2025 Jan;
670:125203.
PMID: 39798625
Skin cancer is prevalent worldwide,surpassing all other forms of cancer and it does not respond effectively to conventional formulations. Treatment of skin cancer further require deeper permeation into the skin....